How do I set a price alert for EMBC?

To set a EMBC price alert on Stock Alarm Pro, navigate to the EMBC quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for EMBC?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for EMBC. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for EMBC?

Stock Alarm Pro supports over 125 trigger types for EMBC: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about EMBC price changes?

EMBC alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for EMBC alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for EMBC and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

Embecta Corp.(EMBC)

$5.70—

WatchlistAsk AI Chart

Embecta Corp.(EMBC)

NASDAQAbout this data

$5.70—

WatchlistAsk AI Chart Studio

EMBC(EMBC)

EMBC

10/5/26

Embecta (EMBC)

Monday

11:23 AM

ThesisEmbecta: the risks are mounting — GLP-1 therapy adoption permanently reducing insulin-dependent diabetes population - Ozempic, Mounjaro…

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$1.1B	$1.0B	$1.1B
Rev. Growth	-3.8%	-5.4%	+4.3%
EPS	$1.64	$1.83	$1.76
EPS Growth	+22.4%	+11.9%	-4.0%
P/E (fwd)	3.4×	3.1×	3.2×

★ Analysts see FY2027 revenue reaching $1.1B — +4.3% growth in a single year.

What Could Go Wrong

01GLP-1 therapy adoption permanently reducing insulin-dependent diabetes population - Ozempic, Mounjaro, and Wegovy demonstrating 15-20% reductions in insulin requirements for Type 2 patients, with ~90% of diabetes market being Type 2
02Biosimilar insulin proliferation shifting delivery methods - lower-cost biosimilars often packaged with prefilled pens rather than vials, reducing syringe demand and potentially disrupting pen needle market share
03Continuous glucose monitoring and automated insulin delivery systems integration - closed-loop systems may favor proprietary delivery mechanisms over commodity pen needles
04Medicare negotiation authority under Inflation Reduction Act - insulin price caps and potential device reimbursement changes could pressure pricing and utilization patterns
05BD (former parent) retains significant diabetes care presence with integrated solutions and established relationships, creating competitive overlap
06Novo Nordisk and Eli Lilly vertical integration - insulin manufacturers increasingly bundling delivery devices with pharmaceuticals, bypassing independent device suppliers
07Private label and low-cost Asian manufacturers in pen needle market - commoditization pressure in undifferentiated product categories
08Elevated leverage with negative equity position (-$2.32 D/E ratio) reflecting spin-off capital structure - limits financial flexibility and increases refinancing risk

FY2025 Snapshot

Revenue: $1.1B
Rev. Growth: -3.8%
Gross Margin: 62.9%
Op. Margin: 30.5%
Net Margin: 8.8%
Net Income: $95M
NI Growth: +21.8%
EPS: $1.64
1Y Return: -60.3%

EMBC Chart

My Notes

value - The stock trades at distressed multiples (0.6x P/S, 5.2x EV/EBITDA) reflecting structural concerns about diabetes care market…
Rising interest rates increase debt service costs on the company's ~$1.3B term loan and revolving credit facilities…
Watch on earnings: US insulin prescription volume trends (IQVIA data) - leading indicator of delivery device demand, GLP-1 therapy market share growth - Ozempic, Mounjaro, Wegovy prescription trends signal insulin displacement, Medicare Part D enrollment and formulary coverage - affects ~30-35% of revenue base.

One Sentence Summary:

The bear case: glp-1 therapy adoption permanently reducing insulin-dependent diabetes population - ozempic, mounjaro.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2025

FY2026E

FY2027E

P/E (fwd)

3.4×

3.1×

3.2×

What Could Go Wrong

01GLP-1 therapy adoption permanently reducing insulin-dependent diabetes population - Ozempic, Mounjaro, and Wegovy demonstrating 15-20% reductions in insulin requirements for Type 2 patients, with ~90% of diabetes market being Type 2

02Biosimilar insulin proliferation shifting delivery methods - lower-cost biosimilars often packaged with prefilled pens rather than vials, reducing syringe demand and potentially disrupting pen needle market share

03Continuous glucose monitoring and automated insulin delivery systems integration - closed-loop systems may favor proprietary delivery mechanisms over commodity pen needles

04Medicare negotiation authority under Inflation Reduction Act - insulin price caps and potential device reimbursement changes could pressure pricing and utilization patterns

05BD (former parent) retains significant diabetes care presence with integrated solutions and established relationships, creating competitive overlap

06Novo Nordisk and Eli Lilly vertical integration - insulin manufacturers increasingly bundling delivery devices with pharmaceuticals, bypassing independent device suppliers

07Private label and low-cost Asian manufacturers in pen needle market - commoditization pressure in undifferentiated product categories

08Elevated leverage with negative equity position (-$2.32 D/E ratio) reflecting spin-off capital structure - limits financial flexibility and increases refinancing risk

My Notes

value - The stock trades at distressed multiples (0.6x P/S, 5.2x EV/EBITDA) reflecting structural concerns about diabetes care market…

Rising interest rates increase debt service costs on the company's ~$1.3B term loan and revolving credit facilities…

Watch on earnings: US insulin prescription volume trends (IQVIA data) - leading indicator of delivery device demand, GLP-1 therapy market share growth - Ozempic, Mounjaro, Wegovy prescription trends signal insulin displacement, Medicare Part D enrollment and formulary coverage - affects ~30-35% of revenue base.